Ads
related to: newest test for prostate cancer- Contact Us
Contact our representatives
for product and reimbursement info.
- Case Studies
Review real case studies
with real patients.
- Find an Imaging Site
Locate the nearest imaging site
or contact customer service.
- Sign Up for Updates
Sign up to receive the latest data,
case studies, and resources.
- Contact Us
Search results
Results from the WOW.Com Content Network
Prostate cancer imaging developed by university researchers has shown “extremely encouraging” results in its first clinical trials. ... The new imaging test begins by injecting a commonly used ...
Researchers found that the test had a 95% sensitivity for prostate cancer of grade group 2 or greater, and 99% for grade group 3 or greater. “It does look impressive and exciting.
To measure the impact of new scans and tests, researchers analysed data from more than 16,000 men referred with suspected prostate cancer in two NHS registries covering 16 hospitals.
n/a Ensembl ENSG00000225937 n/a UniProt n a n/a RefSeq (mRNA) n/a n/a RefSeq (protein) n/a n/a Location (UCSC) Chr 9: 76.69 – 76.86 Mb n/a PubMed search n/a Wikidata View/Edit Human Prostate cancer antigen 3 (PCA3, also referred to as DD3) is a gene that expresses a non-coding RNA. PCA3 is only expressed in human prostate tissue, and the gene is highly overexpressed in prostate cancer ...
Prostate cancer antigen 3 is a urine test that detects the overexpression of the PCA3 gene, an indicator of prostate cancer. [32] [46] [47] [44] ConfirmMDx is performed on tissue taken during a prostate biopsy. The test identifies men with clinically significant prostate cancer who would benefit from further testing and treatment.
Prostate cancer is the second-most frequently diagnosed cancer in men, and the second-most frequent cause of cancer death in men (after lung cancer). [2] [3] Around 1.2 million new cases of prostate cancer are diagnosed each year, and over 350,000 people die of the disease, annually. [2]
Ads
related to: newest test for prostate cancer